BridgeBio Oncology Therapeutics, Inc. (BBOT), a clinical-stage biotechnology company, announced its financial results in its 10-K filing for the year ended December 31, 2025. The company, formed through a business combination with Helix Acquisition Corp. II in August 2025, is focused on developing novel small molecule therapeutics targeting RAS and PI3Kα for cancer treatment. BBOT reported a net loss of $134 million for 2025, compared to a net loss of $74.3 million in 2024. The increased loss reflects escalating research and development expenses as the company advances its pipeline, coupled with general and administrative costs associated with operating as a public entity.
BBOT's research and development expenses for 2025 totaled $121.2 million, a 66% increase from $73.1 million in the previous year. This rise was primarily driven by increased clinical trial and manufacturing expenses related to its three lead product candidates: BBO-8520, BBO-10203, and BBO-11818. General and administrative expenses also saw a significant increase, rising by 217% to $24.6 million in 2025, compared to $7.8 million in 2024. This increase was attributed to personnel-related expenses, professional and consulting fees associated with standalone operations, and a $7.8 million charge related to common stock issued to BridgeBio Pharma.
Operationally, BBOT is currently enrolling patients in Phase 1 clinical trials for all three lead product candidates. BBO-8520, a KRAS G12C inhibitor, is being evaluated both as a monotherapy and in combination with pembrolizumab. BBO-10203, a RAS-PI3Kα breaker, is being studied in patients with HER2+ breast cancer, HR+/HER2- breast cancer, and KRAS mutant colorectal cancer. BBO-11818, a pan-KRAS inhibitor, is being assessed in patients with KRAS mutant solid tumors. The company anticipates sharing additional clinical data from these trials in the second half of 2026. As of December 31, 2025, BBOT had 92 employees.
Looking ahead, BBOT expects to continue incurring significant operating losses as it progresses its clinical trials and expands its research and development efforts. The company estimates that its existing cash, cash equivalents, and short-term marketable securities will be sufficient to fund its operations into early 2028. However, BBOT acknowledges the need to raise additional capital in the future to complete the development and commercialization of its product candidates. The company plans to explore various funding options, including public or private equity financings, debt financings, and strategic collaborations.
About Helix Acquisition Corp. II
Helix Acquisition Corp. II is a Cayman Islands-based special purpose acquisition company (SPAC) formed to identify and merge with target businesses. It has no operations or revenues, raising funds through an IPO and private placements. Its business model involves completing a merger or acquisition within a set timeframe, primarily targeting biotech or healthcare companies, with shareholder redemption rights and a focus on strategic, value-creating transactions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.